ReviewImmunity2023
Dendritic cells as shepherds of T cell immunity in cancer.
Review in Immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 235 citations in OpenAlex.
- A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)Cancer immunology, immunotherapy : CII · 2024Trial
- Mitochondria-targeted photodynamic nanoparticles boost antitumor immunity by suppressing mitophagy in osteosarcoma.Bioactive materials · 2026Article
- Igniting antitumour immunity with cancer cell pyroptosis.Nature reviews. Cancer · 2026Review
- Glutaminolysis Blockade-Empowered Bimodal Nanodepot for Spatially Complementary Sono-Thermal Ablation via PANoptosis and STING Activation Against Large Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1Journal for immunotherapy of cancer · 2026Article
- Recent developments in cancer immuno-interception strategies.Trends in molecular medicine · 2026Review
- Antiviral innate immunity in myocarditis: mechanisms and emerging therapeutics.Experimental & molecular medicine · 2026Review
- Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.Nature cancer · 2026Article
- Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response.Cell death and differentiation · 2026Article
- Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Phototherapy-responsive nanoplatform with hydrogel delivery potentiates immunotherapy and inhibits lung metastasis in osteosarcoma via synergistic glycolysis inhibition and vascular normalization.Journal of nanobiotechnology · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Self-Cooperative RNA Vaccine Mitigates Dendritic Cell-Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response.Journal for immunotherapy of cancer · 2026Article
- Dual-pathway induction of pyroptosisActa pharmaceutica Sinica. B · 2026Article
- Enhanced tumor immunotherapy by nanovesicles derived from engineered DC-like M1 macrophage.Acta pharmaceutica Sinica. B · 2026Article
- Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Review
- Amplifying tumour antigen presentations from intratumourally entrapped dendritic cells.Nature nanotechnology · 2026Article
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
In cancer patients, dendritic cells (DCs) in tumor-draining lymph nodes can present antigens to naive T cells in ways that break immunological tolerance. The clonally expanded progeny of primed T cells are further regulated by DCs at tumor sites. Intratumoral DCs can both provide survival signals to and drive effector differentiation of incoming T cells, thereby locally enhancing antitumor immunity; however, the paucity of intratumoral DCs or their expression of immunoregulatory molecules often limits antitumor T cell responses. Here, we review the current understanding of DC-T cell interactions at both priming and effector sites of immune responses. We place emerging insights into DC functions in tumor immunity in the context of DC development, ontogeny, and functions in other settings and propose that DCs control at least two T cell-associated checkpoints of the cancer immunity cycle. Our understanding of both checkpoints has implications for the development of new approaches to cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.